Rxilient
- Company typePrivate
- Founded2019
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Rxilient does
Rxilient is a Singapore-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2019 and operating with 11 to 50 employees. The company provides CDMO services to pharmaceutical clients, encompassing drug substance development, formulation, and contract manufacturing support typical of regional CDMOs at this scale. Its private, for-profit status and Singapore domicile position it within a recognized regional pharmaceutical hub with established GMP infrastructure and clear bilateral regulatory recognition (US FDA, EMA, HSA), making it a plausible gateway for serving Southeast Asian and broader Asia-Pacific pharmaceutical customers.
The company's go-to-market is built around its CDMO service offering, with revenue mechanics tied to development fees, milestone payments, and commercial manufacturing contracts — the standard monetization model for early- to mid-stage CDMOs. No specific pricing model, customer logos, distribution channels, or detailed product/service breakdowns are disclosed in the available sources; the corporate website returns only a loading/verification page and does not surface substantive company information. As a result, segment focus, customer mix, and contract value ranges cannot be quantified from public material.
In October 2023, Rxilient closed a $30 million funding round led by Pharmaron — a leading global pharmaceutical services and CDMO platform — with participation from Legend Capital. The presence of Pharmaron as lead investor is the most strategically informative signal in the dataset: it ties Rxilient into the orbit of a top-tier global CDMO and likely provides access to technical know-how, capacity, and potentially cross-referral of clients. Given the four-year operating history, sub-50 headcount, and recent sizable raise, the company appears to be in a scale-up phase, deploying capital toward capacity build-out, geographic expansion, or service-line broadening rather than operating as a mature commercial manufacturer.
Rxilient firmographics
Firmographics- Name
- Rxilient
- Website
- https://rxilient.com
- Company type
- Private
- Founded year
- 2019
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Rxilient industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Rxilient is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
Rxilient business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Rxilient product offering
Product offeringCore offering
Rxilient is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides outsourced drug development and manufacturing services to pharmaceutical clients. Founded in 2019 and based in Singapore, the company operates with 11-50 employees to deliver contract manufacturing services in the pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Contract Development and Manufacturing Services Outsourced pharmaceutical drug development and manufacturing services provided to pharmaceutical company clients on a contract basis.
Companies that use Rxilient
Customer profileIdeal customer profiles1 record
Rxilient technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Rxilient partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Rxilient competitors and assessment
Company assessmentDirect peers
- Asymchem Laboratories: Asymchem is a leading China-based CDMO specializing in small-molecule API and intermediates with growing drug product capabilities. It targets similar innovator and generic pharma customers in APAC and globally.
- Pharmaron: Pharmaron is a global integrated CDMO offering drug discovery, development, and manufacturing services across APIs and drug product. It is the lead investor in Rxilient and operates in the same integrated pharmaceutical CDMO space, making it the closest comparable despite its scale advantage.
- WuXi STA: WuXi STA is one of the largest integrated CDMOs globally, offering both small-molecule API and drug product services. It directly competes for the same APAC-based pharmaceutical outsourcing programs that Rxilient targets.
- Cambrex: Cambrex is a US-based small-molecule API and finished dosage CDMO serving innovator and generic pharma customers. It is a direct functional comparable to Rxilient across drug substance and drug product integrated offerings.
- Alcami Corporation: Alcami is a US-based CDMO offering integrated drug substance and drug product services for small molecules and biologics. It is a comparable integrated-pharma CDMO competing for similar mid-sized pharma outsourcing programs.
Regional players
- Samsung Biologics: Samsung Biologics is a leading Asia-based biologics CDMO headquartered in South Korea. While primarily biologics-focused, it competes for integrated CDMO mandates across APAC and represents the regional supply density Rxilient faces.
Broad incumbents
- Catalent: Catalent is a major global CDMO with deep expertise in drug product formulation, softgel, and biologics. It represents the type of incumbent Rxilient must differentiate against for integrated development and manufacturing programs.
- Lonza Group: Lonza is the world's largest CDMO across small molecules, biologics, and cell & gene therapies. It sets the competitive benchmark Rxilient must meet on GMP certification, regulatory track record, and global commercial supply capability.
- Recipharm: Recipharm is a European-headquartered CDMO with broad small-molecule drug product capabilities. It serves similar innovator and generic pharma customers for outsourced development and commercial manufacturing.
- Siegfried Holding: Siegfried is a Swiss-listed integrated CDMO covering APIs and finished dosage forms. It is comparable to Rxilient in target market and service breadth, though at significantly greater scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Rxilient social profiles
Digital presenceRxilient financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rxilient leadership team
Management profileNumber of profiles
Rxilient funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rxilient M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rxilient
What does Rxilient do?
Rxilient is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides outsourced drug development and manufacturing services to pharmaceutical clients. Founded in 2019 and based in Singapore, the company operates with 11-50 employees to deliver contract manufacturing services in the pharmaceutical industry.
When was Rxilient founded?
Rxilient was founded in 2019. It employs 11 to 50 people.
Where is Rxilient based?
Rxilient is headquartered in Singapore, Singapore, in the Asia region.
Who are Rxilient's main competitors?
Direct peers on record are Asymchem Laboratories, Pharmaron, WuXi STA, Cambrex and Alcami Corporation. Samsung Biologics is listed as a regional player. Broad incumbents are Catalent, Lonza Group, Recipharm and Siegfried Holding.
Does Rxilient have an API?
No public API is recorded for Rxilient.
What industry is Rxilient in?
Rxilient's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 3254 and its SIC code is 2834.